Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6624604 | 0.93 | CACNA1C (0.33) | CACNA1CESR1PTGS1PDE4AKDM4E | |
| SCHEMBL6767067 | 0.93 | CACNA1C (0.33) | CACNA1CESR1PTGS1PDE4AKDM4E | |
| SCHEMBL6771009 | 0.92 | CACNA1C (0.34) | CACNA1CESR1PTGS1PDE4AKDM4E | |
| SCHEMBL6772792 | 0.90 | CACNA1C (0.34) | CACNA1CESR1PTGS1PDE4AKDM4E | |
| SCHEMBL6624812 | 0.90 | CACNA1C (0.34) | CACNA1CESR1PTGS1PDE4AKDM4E | |
| SCHEMBL6622380 | 0.90 | CACNA1C (0.34) | CACNA1CESR1PTGS1PDE4AKDM4E | |
| SCHEMBL6623699 | 0.90 | CACNA1C (0.35) | CACNA1CESR1PTGS1PDE4AKDM4E | |
| SCHEMBL6623238 | 0.90 | CACNA1C (0.33) | CACNA1CESR1PTGS1PDE4AKDM4E | |
| SCHEMBL6621372 | 0.90 | CACNA1C (0.35) | CACNA1CESR1PTGS1PDE4AKDM4E | |
| SCHEMBL6772192 | 0.89 | CACNA1C (0.34) | CACNA1CESR1PTGS1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825187-B2 | CARBAPENEM DERIVATIVES SUBSTITUTED AT THE 2-POSITION WITH A SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP; USE AGAINST ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA, ENTEROCOCCI AND INFLUENZA VIRUS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1251134-A1 | NOVEL CARBAPENEM DERIVATIVES OF QUATERNARY SALT TYPE | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | DHPS, HDHD5, RRP15 | CACNA1C 1855/4885ESR1 4807/4885PTGS1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.